Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
基本信息
- 批准号:10463802
- 负责人:
- 金额:$ 267.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-09 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenineAffinityAllelesAnimal ModelAntibody ResponseAntigen ReceptorsBiodiversityBiological AssayBiological MarkersCRISPR/Cas technologyCapsidChinaChronic Obstructive Pulmonary DiseaseClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplexCryoelectron MicroscopyDeaminaseDensitometryDiseaseDisease modelDoctor of PhilosophyElastinEnvironmentEnzymesEuropeanExhibitsFacultyFerretsFutureGene SilencingGene Transduction AgentGenesGeneticGenetic DiseasesHomozygoteHumanHuman GeneticsHybridsImmune EvasionImmune responseImmunologyImpairmentInterferon Type IILaboratoriesLeadLibrariesLifeLiverLungLung CAT ScanLung diseasesMeasurementMeasuresMechanicsMediatingModelingMolecularMusMuscleMutationOther GeneticsOutcomePharmaceutical PreparationsPhenotypePhysiologicalPhysiologyPopulationPropertyProteinsPulmonary EmphysemaPulmonary InflammationRNA-Directed DNA PolymeraseRecombinant adeno-associated virus (rAAV)Regulatory T-LymphocyteResearch PersonnelRoleSafetySerotypingSerumSiteStructure-Activity RelationshipSystemTechnologyTestingTimeTransducersTransgenesTransgenic AnimalsTransgenic OrganismsVariantVeterinary MedicineVeterinary SchoolsWild Type Mouseadeno-associated viral vectorairway obstructionalpha 1-Antitrypsinalpha 1-Antitrypsin Deficiencybasebase editingbase editorcell mediated immune responseclinically relevantcollaborative environmentcomparative efficacydelivery vehicledesignenzyme activityenzyme linked immunospot assaygene delivery systemgene replacementgene therapyimmunogenicimmunoregulationimprovedinnovationmouse modelmutantneutralizing antibodyneutralizing monoclonal antibodiesnew technologynext generationnonhuman primatenovelprime editingprime editorprogramsreconstitutionresponsescreeningsuccesstooltreatment responsevector
项目摘要
Project Summary (OVERALL)
Alpha-1 antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene. The
E342K (PI*Z) mutant allele is very common among those of European ancestry, and E342K
homozygotes encode a protein with impaired secretion, resulting in deficient AAT serum levels.
Since AAT normally protects elastin in the lung from degradation, loss of effective AAT triggers
lung inflammation, airways obstruction and emphysema, which is the primary life-limiting
manifestation of AATD. The projects within this proposal seek to pursue numerous parallel
strategies to develop a gene therapy for AATD. Most of these strategies revolve around the use
of recombinant adeno-associated virus (rAAV)-based vectors, a platform technology that has
been very successful for other genetic diseases. In Project 1, optimized rAAV vectors will be
studied in genetically defined animal models (including mice and ferrets) in comparison with
transgenic reconstitution studies using a regulated conditional transgenic system to compare
two relevant potential target replacement levels (11µM and 25µM) and clinically relevant
endpoints will be studied. In Project 2, novel CRISPR variants will be used for gene editing,
base editing and prime editing strategies to treat AATD. In Project 3, we will screen naturally
occurring AAV capsid libraries obtained from remote populations in Western China to identify
capsids with enhanced efficacy and safety for AATD gene therapy. Finally, in project 4, we will
use novel Treg and CAR-Treg strategies to selectively modulate anti-vector immune responses.
There will also be two cores. Core A will provide each project with important Vector
Immunology assays, which can identify limitations due to host immune responses to AAV
capsids, the AAT transgene or to Cas9-derived proteins. Core B will provide animal models and
physiologic measurements in the animal models for testing of optimized rAAV vectors, gene
editing tools and immune modulation approaches. Program investigators have a track record of
interactions and collaborations that we anticipate will continue in future years.
项目总结(总体)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terence R. Flotte其他文献
Swinging for the fences: persistent and efficient liver-directed gene therapy for hemophilia A
摇摆不定:针对血友病 A 的持续有效的肝脏定向基因治疗
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
Terence R. Flotte - 通讯作者:
Terence R. Flotte
Asymptomatic Chlamydia trachomatis infections among sexually active men.
性活跃男性中的无症状沙眼衣原体感染。
- DOI:
10.1093/infdis/154.5.900 - 发表时间:
1986 - 期刊:
- 影响因子:0
- 作者:
George H. Karam;David H. Martin;Terence R. Flotte;Frank O. Bonnarens;John R. Joseph;Tomasz F. Mroczkowski;William D. Johnson - 通讯作者:
William D. Johnson
Real time laryngoscopy with olfactory challenge for diagnosis of psychogenic stridor
实时喉镜嗅觉激发诊断心因性喘鸣
- DOI:
- 发表时间:
1993 - 期刊:
- 影响因子:3.1
- 作者:
S. Tomares;Terence R. Flotte;D. Tunkel;M. Pao;G. Loughlin - 通讯作者:
G. Loughlin
Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity
对腺相关病毒血清型 2 传递的转基因的免疫力是由自身免疫遗传倾向赋予的
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:5.1
- 作者:
Ying Zhang;Matthew Powers;C. Wasserfall;T. Brusko;Sihong Song;Terence R. Flotte;Richard O. Snyder;Mark Potter;Marda Scott;M. Campbell;James M. Crawford;Harry S. Nick;A. Agarwal;T. Ellis;Mark A. Atkinson - 通讯作者:
Mark A. Atkinson
498. AAV Δ264CFTR Enhances Maturation of ΔF508CFTR and wt CFTR Expression
- DOI:
10.1016/j.ymthe.2006.08.568 - 发表时间:
2006-01-01 - 期刊:
- 影响因子:
- 作者:
Liudmila Cebotaru;Terence R. Flotte;William B. Guggino - 通讯作者:
William B. Guggino
Terence R. Flotte的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Terence R. Flotte', 18)}}的其他基金
Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
- 批准号:
10270089 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
- 批准号:
10463803 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models
针对 AAT 缺陷的优化基因替换以及小型和大型动物模型中的临床结果建模
- 批准号:
10674943 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models
针对 AAT 缺陷的优化基因替换以及小型和大型动物模型中的临床结果建模
- 批准号:
10463807 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
- 批准号:
10674935 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
- 批准号:
10674934 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Models and Gene Therapies for AAT Deficiency
AAT 缺乏症的模型和基因疗法
- 批准号:
10270088 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models
针对 AAT 缺陷的优化基因替换以及小型和大型动物模型中的临床结果建模
- 批准号:
10270092 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency
治疗 Alpha-1 抗胰蛋白酶缺乏症的基因治疗新方法
- 批准号:
9322543 - 财政年份:2016
- 资助金额:
$ 267.67万 - 项目类别:
New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency
治疗 Alpha-1 抗胰蛋白酶缺乏症的基因治疗新方法
- 批准号:
9071187 - 财政年份:2016
- 资助金额:
$ 267.67万 - 项目类别:
相似海外基金
The Role of Adenine Nucleotide Translocase in Mitochondrial Dysfunction Associated Senescence in Chronic Obstructive Pulmonary Disease (COPD)
腺嘌呤核苷酸转位酶在慢性阻塞性肺病(COPD)线粒体功能相关衰老中的作用
- 批准号:
10633608 - 财政年份:2023
- 资助金额:
$ 267.67万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10794933 - 财政年份:2022
- 资助金额:
$ 267.67万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10534031 - 财政年份:2022
- 资助金额:
$ 267.67万 - 项目类别:
Development of nobel assay methods for miRNA and adenine methyltransferase using FRET
使用 FRET 开发 miRNA 和腺嘌呤甲基转移酶的诺贝尔检测方法
- 批准号:
21K05120 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease
健康老龄化和阿尔茨海默病脑细胞 DNA 腺嘌呤甲基化的批判性评估
- 批准号:
10365337 - 财政年份:2021
- 资助金额:
$ 267.67万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10033546 - 财政年份:2020
- 资助金额:
$ 267.67万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10613902 - 财政年份:2020
- 资助金额:
$ 267.67万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10226235 - 财政年份:2020
- 资助金额:
$ 267.67万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10396102 - 财政年份:2020
- 资助金额:
$ 267.67万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10705982 - 财政年份:2020
- 资助金额:
$ 267.67万 - 项目类别: